±èÁÖÇ×
¾ÏÁ¤¹ÐÀÇ·á¼¾ÅÍÀå
¼Ò
¼Ó
: ºÐ´çÂ÷º´¿ø
Àü¹®ºÐ¾ß : Æó¾Ï, µÎ°æºÎ¾Ï, ½Äµµ¾Ï
Á÷
ˤ
: ±³¼ö(¾ÏÁ¤¹ÐÀÇ·á¼¾ÅÍÀå)
¸Þ
ÀÏ
:
ºñ°ø°³
Àü
È
:
1577-4488
ÆÑ
½º
:
ÁÖ
¼Ò
:
°æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßžµ¿ 351¹øÁö
ȨÆäÀÌÁö:
ÅǸ޴º
ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£
±¸ºÐ
Á¦¸ñ
´Ù¿î·Îµå
124
ÇØ¿Ü
Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations
123
ÇØ¿Ü
Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma
122
ÇØ¿Ü
A prospective phase II trial of S-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer
121
ÇØ¿Ü
Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma
120
ÇØ¿Ü
A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes
119
ÇØ¿Ü
Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer
118
ÇØ¿Ü
S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: Phase II trial
117
ÇØ¿Ü
Glycolysis Inhibition Sensitizes Non-Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation
116
ÇØ¿Ü
Better Outcome of XELOX Chemotherapy in Patients with Advanced Intestinal-Type Adenocarcinoma of the Ampulla of Vater
115
±¹³»
Prognostic Value of 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients with Resectable Pancreatic Cancer
1
2
3
4
5
6
7
8
9
10
Copyright ¨Ï chamc, All rights reserved.
ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à
Àüȹ®ÀÇ
°³²Â÷º´¿ø 02.3468.3000
ºÐ´çÂ÷º´¿ø 031.780.5000
Â÷¿ò 02.3015.5300
±¸¹ÌÂ÷º´¿ø 054.450.9700
´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
°³²°ÇÁø¼¾ÅÍ 02.2191.3900
ºÐ´çÁ¾ÇÕ°Ç°ÁõÁø¼¾ÅÍ 031.780.5940
½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729